Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its position in Moderna, Inc. (NASDAQ:MRNA) by 43.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 115,828 shares of the company’s stock after selling 89,169 shares during the quarter. Handelsbanken Fonder AB’s holdings in Moderna were worth $11,519,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Allworth Financial LP lifted its stake in shares of Moderna by 6.5% in the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock valued at $165,000 after purchasing an additional 101 shares during the period. TIAA Trust National Association lifted its stake in shares of Moderna by 2.3% in the 4th quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after purchasing an additional 102 shares during the period. Sound Income Strategies LLC lifted its stake in shares of Moderna by 17.8% in the 4th quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock valued at $76,000 after purchasing an additional 115 shares during the period. Newbridge Financial Services Group Inc. lifted its stake in shares of Moderna by 7.2% in the 3rd quarter. Newbridge Financial Services Group Inc. now owns 1,776 shares of the company’s stock valued at $183,000 after purchasing an additional 120 shares during the period. Finally, IFP Advisors Inc lifted its stake in shares of Moderna by 18.8% in the 3rd quarter. IFP Advisors Inc now owns 834 shares of the company’s stock valued at $86,000 after purchasing an additional 132 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Trading Up 3.3 %

Shares of MRNA opened at $107.89 on Wednesday. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $142.79. The firm has a 50-day moving average price of $101.39 and a 200 day moving average price of $93.53. The firm has a market capitalization of $41.31 billion, a P/E ratio of -8.69 and a beta of 1.62.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The firm had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.53 billion. During the same quarter in the prior year, the firm posted $3.61 earnings per share. Moderna’s quarterly revenue was down 44.9% on a year-over-year basis. Sell-side analysts forecast that Moderna, Inc. will post -7.51 EPS for the current year.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 544 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $99.05, for a total value of $53,883.20. Following the completion of the sale, the insider now owns 9,267 shares of the company’s stock, valued at $917,896.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Shannon Thyme Klinger sold 544 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $99.05, for a total transaction of $53,883.20. Following the sale, the insider now owns 9,267 shares of the company’s stock, valued at $917,896.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Stephen Hoge sold 2,388 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the sale, the president now directly owns 1,515,898 shares in the company, valued at approximately $143,358,473.86. The disclosure for this sale can be found here. Over the last quarter, insiders sold 109,954 shares of company stock valued at $11,533,976. 15.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on MRNA. Royal Bank of Canada reiterated an “outperform” rating and issued a $125.00 target price on shares of Moderna in a research note on Thursday, March 28th. HSBC reissued a “reduce” rating and issued a $86.00 price target (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Oppenheimer raised shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target for the company in a report on Tuesday, January 2nd. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Thursday, April 11th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Moderna has a consensus rating of “Hold” and a consensus target price of $126.49.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.